###begin article-title 0
RUNX3 Has an Oncogenic Role in Head and Neck Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: YK. Performed the experiments: TT YK SI IO YA. Analyzed the data: TT YK SI IO YA TT. Contributed reagents/materials/analysis tools: YK TF HK YA. Wrote the paper: YK TT.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 350 355 <span type="species:ncbi:9606">human</span>
Runt-related transcription factor 3 (RUNX3) is a tumor suppressor of cancer and appears to be an important component of the transforming growth factor-beta (TGF-ss)-induced tumor suppression pathway. Surprisingly, we found that RUNX3 expression level in head and neck squamous cell carcinoma (HNSCC) tissues, which is one of the most common types of human cancer, was higher than that in normal tissues by a previously published microarray dataset in our preliminary study. Therefore, here we examined the oncogenic role of RUNX3 in HNSCC.
###end p 3
###begin title 4
Principal Findings
###end title 4
###begin p 5
Frequent RUNX3 expression and its correlation with malignant behavior were observed in HNSCC. Ectopic RUNX3 overexpression promoted cell growth and inhibited serum starvation-induced apoptosis and chemotherapeutic drug induced apoptosis in HNSCC cells. These findings were confirmed by RUNX3 knockdown. Moreover, RUNX3 overexpression enhanced tumorsphere formation. RUNX3 expression level was well correlated with the methylation status in HNSCC cells. Moreover, RUNX3 expression was low due to the methylation of its promoter in normal oral epithelial cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
Our findings suggest that i) RUNX3 has an oncogenic role in HNSCC, ii) RUNX3 expression observed in HNSCC may be caused in part by demethylation during cancer development, and iii) RUNX3 expression can be a useful marker for predicting malignant behavior and the effect of chemotherapeutic drugs in HNSCC.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX1</italic>
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX2</italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 175 186 175 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CBFB/Pebpb2</italic>
###xml 287 290 287 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Ito1">[1]</xref>
###xml 366 369 366 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Bae1">[2]</xref>
###xml 518 521 518 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Bae1">[2]</xref>
###xml 662 665 662 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 784 787 784 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Ito2">[4]</xref>
###xml 953 956 953 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim1">[5]</xref>
###xml 957 960 957 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Yanada1">[8]</xref>
###xml 1060 1063 1060 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim2">[9]</xref>
###xml 1094 1099 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1185 1188 1185 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 1190 1193 1190 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim1">[5]</xref>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 717 722 <span type="species:ncbi:9606">human</span>
###xml 1133 1138 <span type="species:ncbi:9606">human</span>
RUNX3/AML2/PEBP2C/CBFA3 is a transcription factor and one of the Runt-related (RUNX) family. Three members of the Runx family genes, RUNX1, RUNX2 and RUNX3, and related gene, CBFB/Pebpb2, are all known as the developmental regulators and have been shown to be important in human cancers [1]. RUNX3 was originally cloned as AML2 and is localized on chromosome 1p36.1 [2]. RUNX3 has multiple functions and was at first reported to correlate with the genesis and progression of human gastric cancer as a tumor suppressor [2]. Runx3-null mice exhibit hyperplasia of gastric mucosa as a result of stimulated proliferation and suppressed apoptosis of epithelial cells [3]. In fact, RUNX3 is inactivated in more than 80% of human gastric cancer by gene silencing and protein mislocalization [4]. Besides gastric cancer, it has been reported that reduced expression of RUNX3 was observed in various cancers including bladder, liver, colorectal and lung cancers [5]-[8]. In these tumors, reduced expression of RUNX3 was frequently caused by CpG island hypermethylation [9]. Moreover, point mutations of RUNX3 were observed in certain type of human cancers including gastric and bladder cancers [3], [5]. Taken together, RUNX3 acts as a tumor suppressor in various cancers.
###end p 9
###begin p 10
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Mao1">[10]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Fidler1">[11]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Ginos1">[12]</xref>
###xml 537 546 537 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g001">Figure 1A</xref>
###xml 665 669 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-SaltoTellez1">[13]</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of human cancer, with an annual incidence of more than 500,000 cases worldwide [10]. Like most epithelial cancers, HNSCC develops through the accumulation of multiple genetic and epigenetic alterations in a multi-step process [11]. Surprisingly, we found that RUNX3 expression level in HNSCC tissues was higher than that in normal tissues by a previously published microarray dataset of 41 HNSCC patients and 13 normal controls in our preliminary study [12] (Figure 1A). Interestingly, it recently has been reported that RUNX3 overexpression was observed in basal cell carcinoma of skin [13]. Therefore, we thought that RUNX3 might have an oncogenic role in HNSCC as well as in basal cell carcinoma of skin. In the present study, we examined the expression and roles of RUNX3 for HNSCC development.
###end p 10
###begin title 11
Expression of RUNX3 mRNA and protein in HNSCC.
###end title 11
###begin p 12
A: Total RNA from 41 primary HNSCC and 13 normal tissues was labeled and hybridized to Affymetrix U133A Gene Chips as previously reported. Graph shows the average of signal intensity of RUNX3 in 41 HNSCC and 13 normal tissues in microarray analysis. RUNX3 expression level in HNSCC is higher than that of normal tissues. B: Expression of RUNX3 mRNA in 14 HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-N-1, Ho-1-U-1, ZA, HOC719-PE, HOC719-NE, HOC621, HOC119, HOC313, TSU and OMI) by RT-PCR. GAPDH was used as a control. C: Expression of RUNX3 mRNA in various cancer cell lines including colon cancer (RKO and HCT116), gastric cancer (MKN-1 and MKN-45), leukemia (HL60), lymphoma (U937) and breast cancer (MCF7 and SK-BR3). GAPDH was used as a control. D: Expression of RUNX3 mRNA in 18 HNSCC cases by RT-PCR. GAPDH was used as a control. E: Expression of RUNX3 protein in 6 HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-N-1 and Ho-1-U-1) was examined by Western blot analysis. Cul1 expression was used as a loading control.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
Reagents
###end title 14
###begin p 15
Transforming growth factor ss1 (TGF-ss), basic fibroblast growth factor (bFGF) and Platelet-derived growth factor-AA (PDGF-AA) were obtained from R&D systems (Minneapolis, MN). Insulin growth factor (IGF) was obtained from Sigma (Saint Louis, MO). Epidermal growth factor (EGF) was obtained from Pepro Tech EC (London, UK). Adriamycin (Doxorubicin hydrochloride) was obtained from Sigma.
###end p 15
###begin title 16
Cell lines and tissue samples
###end title 16
###begin p 17
###xml 781 782 781 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 972 977 <span type="species:ncbi:10090">mouse</span>
###xml 1032 1036 <span type="species:ncbi:10090">mice</span>
HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-U-1 and Ho-1-N-1) were provided by Japanese Collection of Research Bioresources Cell Bank. HNSCC cell lines (ZA, HOC719-PE, HOC-719-NE, HOC621, HOC119, HOC313, TSU and OMI) were kindly provided by Dr. Kamata (Hiroshima University). Gastric cancer cell lines (MKN-1 and MKN-45), colon cancer cell lines (RKO and HCT116), breast cancer cell lines (MCF7 and SK-BR3), lymphoma cell line (U937) and leukemia cell line (HL-60) were provided by Japanese Collection of Research Bioresources Cell Bank. They were maintained in RPMI-1640 or Dulbecco's Modified Eagle Medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-inactivated FBS (Invitrogen) and 100 U/ml penicillin-streptomycin (Gibco) under conditions of 5% CO2 in air at 37degreesC. For growth assay, 5000 cells were plated onto 24 well plates (Falcon), and trypsinized cells counted at 0, 2, 4, 6 day by Cell Counter (Coulter Z1). Tongue tissues of mouse embryos at embryonic day 15.5 and 10 weeks old BALB/c mice were used for histology and immunohistochemistry. The experimental protocols were approved by the Animal Care and Use Committee of Hiroshima University.
###end p 17
###begin p 18
###xml 189 196 <span type="species:ncbi:9606">patient</span>
Tissue samples of HNSCC were retrieved from the Surgical Pathology Registry of Hiroshima University Hospital, after approval by the Ethical Committee of Hiroshima University Hospital. Each patient gave written informed consent. Fifty-two cases of HNSCC and 9 normal oral mucosal tissues were used in this study. Five colon cancer tissues were also used for immunohistochemistry analysis (kindly provided by Dr. Shimamoto, Prefectural University of Hiroshima).
###end p 18
###begin p 19
10% buffered-formalin fixed and paraffin embedded tissues were used for immunohistochemical examination. The histological grade and stage of tumor were classified according to the criteria of the Japan Society for Head and Neck Cancer. Fresh samples were taken from the HNSCC tissues for RT-PCR analysis.
###end p 19
###begin title 20
RT-PCR
###end title 20
###begin p 21
###xml 362 388 358 384 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGAAGCTGGAGGACCAGAC-3&#8242;</named-content>
###xml 409 435 405 431 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCGGAGAATGGGTTCAGTTC-3&#8242;</named-content>
Total RNA was isolated from cultures of confluent cells using the RNeasy Mini Kit (Qiagen). Preparations were quantified and their purity was determined by standard spectrophometric methods. cDNA was synthesized from 1 microg total RNA according to the ReverTra Dash (Toyobo Biochemicals, Tokyo, Japan). PCR amplification of RUNX3 was done using forward primer; 5'-CAGAAGCTGGAGGACCAGAC-3' and reverse primer; 5'-TCGGAGAATGGGTTCAGTTC-3'. GAPDH was used as a control. Aliquots of total cDNA were amplified with Go Taq(R) Green Master Mix (Promega), and amplifications were performed in a PC701 thermal cycler (Astec, Fukuoka, Japan) for 30 cycles after an initial 30 sec denaturation at 94degreesC, annealed for 30 sec at 60degreesC, and extended for 1 min at 72degreesC in all primers. The amplification reaction products were resolved on 1.5% agarose/TAE gels (Nacalai tesque, Inc., Kyoto, Japan), electrophoresed at 100 mV, and visualized by ethidium-bromide staining.
###end p 21
###begin title 22
Western blot analysis
###end title 22
###begin p 23
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kitajima1">[14]</xref>
Western blotting was carried out as we described previously [14]. An anti-RUNX3 monoclonal antibody (R3-5G4, kindly provided by Dr. Ito, Institute of Molecular and Cell Biology, Singapore), anti-FLAG monoclonal antibody (M2, Sigma) and anti-Cul1 polyclonal antibody (Zymed) were used. Thirty microg of protein was subjected to 10% polyacrylamide gel electrophoresis followed by electroblotting onto a nitrocellulose filter. For detection of the immuno-complex, the ECL western blotting detection system (Amersham) was used.
###end p 23
###begin title 24
Immunohistochemical staining
###end title 24
###begin p 25
###xml 204 208 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kitajima1">[14]</xref>
###xml 1239 1240 1235 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 741 746 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical detection of RUNX3 in HNSCC cases was performed on 4.5 microm sections mounted on silicon-coated glass slides, using a streptavidin-biotin peroxidase technique as described previously [14]. Immunohistochemical detection of Runx3 in human various cancer cases including 3 esophagus cancers, 3 gastric cancers, 3 colon cancers, 3 rectum cancers, 3 pancreas cancers, 3 liver cancers, 3 lung cancers, 3 kidney cancers, 3 bladder cancers, and 4 uterus cancers was performed using tissue microarray (MBL Co. Ltd., Nagoya, Japan). For immunohistochemical study, an anti-RUNX3 monoclonal antibody (R3-6E9, kindly provided by Dr. Ito, Institute of Molecular and Cell Biology, Singapore) was used. For immunohistochemical study of mouse tissues, an anti-Runx3 monoclonal antibody (R3-1E10, MBL Co. Ltd.) was used. The expression of RUNX3 was graded as positive (over 5% of tumor or epithelial cells showed immunopositivity) and negative (less than 5% of tumor or epithelial cells showed weak or focal immunopositivity or no staining). Three pathologists (Y.K., I.O., and T.T.) made all the assessments. Possible correlation between variables of the analyzed tumor samples was tested for association by the Fisher's exact test. A P value<0.05 was required for significance.
###end p 25
###begin title 26
5-aza-2'-deoxycytidine treatment
###end title 26
###begin p 27
HSC4 cells and normal epithelial cells were treated with medium containing 300 nM 5-aza-2'-deoxycytidine (5-aza-dC, Sigma) for 72 h. After treatment, cells were collected and examined the expression of RUNX3 mRNA by RT-PCR.
###end p 27
###begin title 28
Bisulfite modification and methylation-specific polymerase chain reaction (PCR)
###end title 28
###begin p 29
###xml 1592 1601 1526 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2B</xref>
###xml 1653 1661 1587 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s001">Table S1</xref>
###xml 1698 1702 1632 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Homma1">[15]</xref>
Genomic DNA from cells or tissues was extracted using the DNeasy Kit (Qiagen, Hilden, Germany). Fifty micro liters of the supernatant were used directly as a source of DNA for sodium bisulfite treatment. DNA samples were treated with bisulfite to convert all unmethylated cytosines to uracils whilst leaving methylated cytosines unaffected. DNA was denatured by NaOH (final concentration, 0.2 M) for 10 min at 37degreesC. Thirty microl of 10 mM hydroquinone (Sigma) and 520 microl of 3 M sodium bisulfite (Sigma) at pH 5.0 both freshly prepared, were added and mixed, and samples were incubated at 50degreesC for 16 h. Modified DNA was purified using Wizard DNA purification resin (Promega) and eluted into 50 microl of water. Modification was completed by NaOH (final concentration, 0.3 M) treatment for 5 min at room temperature, followed by ethanol precipitation. Modified DNAs were amplified in a 20 microL reaction volume containing 2 microL 10xPCR buffer with 15 mM MgCl2, 4 microL 5xQ-Solution, 10 pM of each primer, 0.2 mM dNTPs and 0.75 U Taq polymerase (HotStar Taq DNA polymerase; Qiagen, Hilden, Germany). After the mixture was heated at 95degreesC for 15 min, PCR was performed in a thermal cycler (GeneAmp 2400; PE Applied Biosystems, Foster City, CA, USA) for 35 cycles of denaturation at 94degreesC for 30 sec, annealing at 58degreesC for 60 sec, and extension at 72degreesC for 60 sec, followed by a final 10 min extension at 72degreesC. The PCR products were separated on a 8% non-denaturing polyacrylamide gel. RUNX3 CpG island and analyzed regions (No. 1-10) are shown in Figure 2B. The primer sets used in this study were listed in Table S1 (GenBank accession number AL023096) [15].
###end p 29
###begin title 30
Immuno-expression of RUNX3 in HNSCC.
###end title 30
###begin p 31
A: Expression of RUNX3 was examined in skin epithelium (x100 and x250, upper panel), normal oral mucosae (x100 and x250, middle panel) and normal oral mucosae with infiltration of chronic inflammatory cells (x100 and x250, lower panel). In skin epithelium, some of epidermal cells showed RUNX3 expression in its nuclei. In normal oral mucosal tissues, only a few epithelial cells in basal layer expressed RUNX3 in their nuclei, and most epithelial cells did not express RUNX3. In normal oral mucosae with infiltration of chronic inflammatory cells, lymphocytes infiltrating into oral mucosa showed RUNX3 expression. B: Expression of RUNX3 was examined in HNSCC cases (x100). Most cancer cells expressed RUNX3 in their nuclei.
###end p 31
###begin title 32
Generation of RUNX3-overexpressing HNSCC cells
###end title 32
###begin p 33
A RUNX3 expression plasmid, pcDNA3 encoding FLAG tagged RUNX3 cDNA, was kindly provided by Dr. Ito (Institute of Molecular and Cell Biology, Singapore). The RUNX3/pcDNA3 plasmid or the vector alone was introduced into HSC3 cells, and then G418 (500 microg/ml, Gibco) was added to the culture medium after 48 h of transfection. After 2 weeks of G418 selection, we obtained the stable pool clones. Cell transfections were performed using FuGENE 6 (Roche) according to the manufacture's instruction.
###end p 33
###begin title 34
Silencing by Small Interfering RNA
###end title 34
###begin p 35
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Elbashir1">[16]</xref>
###xml 453 478 453 478 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ccuucaaggugguggcauu-3&#8242;</named-content>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 544 547 <span type="species:ncbi:10116">rat</span>
###xml 549 554 <span type="species:ncbi:10090">mouse</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
Logarithmically growing Ca9-22 cells were seeded at a density of 105cells/6 cm dish and transfected with oligos twice (at 24 and 48 h after replating) using Oligofectamine (Invitrogen) as described [16]. Forty-eight hours after the last transfection, lysates were prepared and analyzed by SDS-PAGE and immunoblotting. The siRNA is a 19-bp duplex oligoribonucleotide with a sense strand corresponding to nucleotides 275-293 of human RUNX3 mRNA sequence; 5'-ccuucaaggugguggcauu-3'. A scrambled sequence that does not show significant homology to rat, mouse or human gene sequences was used as a control.
###end p 35
###begin title 36
Flow cytometric analysis
###end title 36
###begin p 37
Cell cycle distribution was determined by DNA content analysis after propidium iodide staining. Cells were cultured as described above, and fixed in 70% ethanol and stored at 4degreesC before analysis. Flow cytometric determination of DNA content was analyzed by a FACS calibur (Becton-Dickinson, San Jose, CA) flow cytometer. For each sample, 20,000 events were stored.
###end p 37
###begin title 38
Annexin V and Propidium Iodide Dual-Staining Assay
###end title 38
###begin p 39
After serum starvation or Dox treatment, the cells were then stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI), using the Annexin V-FITC Apoptosis Detection kit (Becton-Dickinson) according to the manufacturer's instructions. Apoptotic cells were identified by dual-staining with recombinant FITC-conjugated with Annexin V and propidium iodide (PI). Data acquisition and analysis were done in a FACSCalibur (Becton-Dickinson) flow cytometer using CellQuest software.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
Highly expression of RUNX3 in HNSCC
###end title 41
###begin p 42
###xml 231 240 231 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g001">Figure 1B</xref>
###xml 372 375 372 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 377 380 377 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim1">[5]</xref>
###xml 727 736 727 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g001">Figure 1C</xref>
###xml 904 908 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Cheng1">[17]</xref>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Lau1">[20]</xref>
###xml 1002 1006 1002 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Lau1">[20]</xref>
###xml 1146 1155 1146 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g001">Figure 1D</xref>
###xml 1295 1304 1295 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g001">Figure 1E</xref>
###xml 1636 1640 1636 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-SaltoTellez1">[13]</xref>
###xml 1702 1711 1702 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2A</xref>
###xml 1846 1850 1846 1850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Takahashi1">[18]</xref>
###xml 1875 1879 1875 1879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Takahashi1">[18]</xref>
###xml 1991 2000 1991 2000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s003">Figure S1</xref>
###xml 2163 2172 2163 2172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2A</xref>
###xml 2263 2272 2263 2272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2A</xref>
###xml 2443 2452 2443 2452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2B</xref>
###xml 2700 2707 2700 2707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005892-t001">Table 1</xref>
###xml 2980 2987 2980 2987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005892-t001">Table 1</xref>
###xml 262 267 <span type="species:ncbi:9606">human</span>
First, we examined the expression of RUNX3 in 14 HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-U-1, Ho-1-N-1, ZA, HOC719-PE, HOC719-NE, HOC621, HOC119, HOC313, TSU, and OMI). RUNX3 mRNA was observed in 9 of 14 HNSCC cell lines (Figure 1B). In certain type of human cancers including gastric and bladder, it has been reported that point mutations of RUNX3 were observed [3], [5]. However, no mutations were found in HNSCC cell lines with RUNX3 mRNA expression (Ca9-22, Ho-1-U-1 and Ho-1-N-1) (data not shown). RUNX3 mRNA expression was also examined in various cancer cell lines including colon cancer (RKO and HCT116), gastric cancer (MKN-1 and MKN-45), leukemia (HL60), lymphoma (U937) and breast cancer (MCF7 and SK-BR3) (Figure 1C). RKO, MCF7 and SK-BR3 cells did not express RUNX3 mRNA. As previously reported, RUNX3 expression was well correlated with methylation status, except for SK-BR3 cells [17]-[20]. In SK-BR3 cells, down-regulation of RUNX3 is thought to be caused by unknown mechanism [20]. We also examined the expression of RUNX3 mRNA in 18 HNSCC tissues. In 13 of 18 (72.2%) HNSCC tissues, RUNX3 mRNA expression was observed (Figure 1D). Next, RUNX3 protein expression was examined by Western blot analysis in 6 HNSCC cells (HSC2, HSC3, HSC4, Ca9-22, Ho-1-U-1 and Ho-1-N-1) (Figure 1E). Among them, Ca9-22, Ho-1-U-1 and Ho-1-N-1 cells expressed RUNX3 protein, corresponding to mRNA expression. Then, we examined RUNX3 expression in 9 normal oral mucosal tissues and 52 HNSCC cases by immunohistochemistry. First, we used skin epithelium and colon mucosa for reactivity of RUNX3 expression. As shown in recent report [13], epidermal cells also showed RUNX3 expression in its nuclei (Figure 2A, upper panel). We also examined the RUNX3 expression in colon cancer. In colon cancer, RUNX3 is thought to be a tumor suppressor gene [18]. As previously reported [18], RUNX3 expression was observed in its nuclei of normal mucosa, while colon cancer cells did not express RUNX3 (Figure S1). In normal oral mucosal tissues, only a few epithelial cells in basal layer slightly expressed RUNX3 in their nuclei, and most epithelial cells did not express (Figure 2A, middle panel). Lymphocytes infiltrating into normal oral mucosa showed RUNX3 expression (Figure 2A, lower panel). Immunopositivity of RUNX3 in lymphocytes was used as a positive control of staining. On the other hand, most cancer cells expressed RUNX3 in their nuclei (Figure 2B). We also confirmed that nuclear expression of RUNX3 by using nuclear and cytoplasmic fraction of HNSCC cell lines, indicating no protein mislocalization (data not shown). RUNX3 expression was frequently observed in 50% (26 of 52) of HNSCC cases (Table 1). Moreover, we compared RUNX3 expression with clinico-pathological findings including differentiation, invasiveness and metastasis. Interestingly, RUNX3 expression was well correlated with malignant behaviors including poorly differentiation, invasiveness and metastasis (Table 1).
###end p 42
###begin title 43
Runx3 expression in normal oral mucosa and HNSCC.
###end title 43
###begin p 44
Runx3 expression is graded as negative (less than 5% of positive cells) and positive (over 5% of positive cells).
###end p 44
###begin p 45
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Jacobsson1">[38]</xref>
The grading of invasion is according to the classification described by Jakobsson et al. as patterns I, II, III and IV [38].
###end p 45
###begin title 46
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
Methylation status of RUNX3 was well correlated with its mRNA expression in HNSCC
###end title 46
###begin p 47
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim2">[9]</xref>
###xml 285 294 285 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3A</xref>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 595 604 595 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3B</xref>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Homma1">[15]</xref>
###xml 627 632 627 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 796 812 796 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3C and 3D</xref>
###xml 914 923 914 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3D</xref>
###xml 1047 1052 1047 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
We asked how RUNX3 expression was caused by in HNSCC. Reduced expression of RUNX3 was frequently caused by CpG island hypermethylation in various types of cancer [9]. In fact, RUNX3 expression was observed in HSC4 cells without RUNX3 expression after 5-aza-2'-deoxycytidine treatment (Figure 3A). Homma et al. examined the methylation status of multiple regions of RUNX3 promoter CpG island (3478 bp) within the proximal promoter (No. 1-10) in gastric cancers and found that methylation at the region spanning the transcription start site (No. 5-8) is critical for loss of the RUNX3 expression (Figure 3B) [15]. To examine the RUNX3 methylation status in HNSCC, we analyzed the methylation of RUNX3 at all promoter regions (No. 1-10) by methylation-specific PCR on the panel of HNSCC cell lines (Figure 3C and 3D). HNSCC cells with RUNX3 expression showed unmethylation or partially methylation at No. 5-8 region (Figure 3D). HNSCC cells without RUNX3 expression showed fully methylation at No. 5 and No. 6 region. Thus, methylation status of the RUNX3 promoter region was well correlated with RUNX3 mRNA expression in HNSCC cell lines.
###end p 47
###begin title 48
Methylation status in normal oral epithelial cells and HNSCC.
###end title 48
###begin p 49
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 742 747 <span type="species:ncbi:10090">mouse</span>
###xml 814 819 <span type="species:ncbi:10090">mouse</span>
###xml 863 868 <span type="species:ncbi:10090">mouse</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
A: RUNX3 expression was examined after 5-aza-2'-deoxycytidine (5-Aza) treatment. HSC4 cells were treated with medium containing 300 nM 5-aza-2'-deoxycytidine for 72 h. After treatment, cells were collected and examined the expression of RUNX3 mRNA by RT-PCR. B: RUNX3 CpG island and analyzed regions (No. 1-10) are shown as vertical bars. Transcriptional start site (TSS) is located within region No. 7. C: Methylation status of RUNX3 in HNSCC cell lines. Genomic DNA was extracted from HNSCC cell lines and was treated with bisulfite. Methylation status of promoter region (No. 1-10) was examined by methylation specific PCR method. D: The summary of methylation and expression status of RUNX3 in HNSCC cell lines. E: Expression of Runx3 in mouse tongue epithelium of embryo (upper panel) and adult (lower panel) mouse by immunohistochemistry. Tongue tissues of mouse embryos at embryonic day 15.5 and 10 weeks old BALB/c mice were used. F: RUNX3 mRNA expression was examined by RT-PCR in 4 primary cultured normal oral epithelial cells (#1-#4). HSC4 cell was used as a negative control and Ca9-22 cell was used as a positive control for RUNX3 expression. GAPDH was used as a control. G: RUNX3 expression was examined after 5-aza-2'-deoxycytidine (5-Aza) treatment. Primary cultured normal oral epithelial cells (#1 and #2) were treated with medium containing 300 nM 5-aza-2'-deoxycytidine for 72 h. After treatment, cells were collected and examined the expression of RUNX3 mRNA by RT-PCR. H: Genomic DNA was extracted from 4 primary cultured normal oral epithelial cells (#1-#4). Methylation status at region No. 5-8 was examined by methylation specific PCR method. I: The summary of methylation and expression status of RUNX3 in normal epithelial cells.
###end p 49
###begin p 50
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Yamamoto1">[21]</xref>
###xml 390 399 390 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3E</xref>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 610 619 610 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2A</xref>
###xml 899 908 899 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2A</xref>
###xml 1020 1029 1020 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3F</xref>
###xml 1319 1328 1319 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3G</xref>
###xml 1357 1362 1357 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1555 1560 1555 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 1639 1648 1639 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3C</xref>
###xml 1882 1898 1882 1898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3H and 3I</xref>
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 310 315 <span type="species:ncbi:10090">mouse</span>
###xml 350 355 <span type="species:ncbi:10090">mouse</span>
Recent report shows that Runx3 is expressed in the tongue and palate epithelium of mouse embryos from embryonic day 12.5 to 16.5, and that Runx3 expression decreases after embryonic day 16.5 and disappears in newborn mice [21]. Here we also confirmed that Runx3 expression was observed in tongue epithelium of mouse embryos (E15.5), but not in adult mouse tongue epithelium (10 weeks old) (Figure 3E). These findings made us hypothesize that RUNX3 might be silenced by methylation in adult oral epithelial cells. Oral mucosal tissue usually contains connective tissue and infiltrating lymphocytes. As shown in Figure 2A (lower panel), lymphocytes infiltrating into normal oral mucosa showed RUNX3 expression. Therefore, we used primary cultured epithelial cells obtained from normal oral epithelium in this study for avoiding contamination of lymphocytes. In similar to immunohistochemical studies (Figure 2A), 4 primary cultured epithelial cells obtained from normal oral epithelium (#1-#4) did not express RUNX3 mRNA (Figure 3F), indicating that expression level of RUNX3 is low or absent in adult normal oral epithelium. We examined the RUNX3 expression after 5-aza-2'-deoxycytidine treatment. RUNX3 expression was up-regulated by 5-aza-2'-deoxycytidine treatment in 2 primary cultured epithelial cells (#1 and #3) (Figure 3G). Then, we examined whether RUNX3 was silenced by methylation in adult oral epithelial cells. We performed methylation-specific PCR in 4 primary cultured epithelial cells at the region spanning the transcription start site of RUNX3 (No. 5-8), which is critical for loss of the RUNX3 expression in HNSCC cells (Figure 3C). Interestingly, 2 primary cultured epithelial cells (#1 and #2) showed partially methylation at No. 6 and No. 7 region, and another 2 primary cultured epithelial cells (#3 and #4) showed fully methylation at No. 7 and No. 8 region (Figure 3H and 3I).
###end p 50
###begin title 51
RUNX3 overexpression enhanced cell proliferation and inhibited apoptosis
###end title 51
###begin p 52
###xml 188 197 188 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g004">Figure 4A</xref>
###xml 258 267 258 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g004">Figure 4B</xref>
###xml 472 481 472 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s004">Figure S2</xref>
###xml 637 646 637 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g004">Figure 4C</xref>
###xml 852 861 852 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g004">Figure 4D</xref>
###xml 1426 1436 1426 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s005">Figure S3A</xref>
###xml 1587 1596 1587 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g005">Figure 5A</xref>
###xml 1853 1863 1853 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s005">Figure S3B</xref>
###xml 1921 1930 1921 1930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g005">Figure 5B</xref>
###xml 2122 2131 2122 2131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g005">Figure 5C</xref>
###xml 2265 2274 2265 2274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g005">Figure 5D</xref>
To know the role of RUNX3 in HNSCC, we stably transfected an expression vector of FLAG-RUNX3 into HSC3 cells with lower expression of RUNX3. We obtained stably RUNX3 overexpressing cells (Figure 4A). Interestingly, RUNX3 overexpression enhanced cell growth (Figure 4B). At 6day, number of RUNX3 overexpressing cells was remarkably higher than that of control cells. Although we examined migration and invasion, RUNX3 overexpression did not promote migration and invasion (Figure S2). Moreover, increased population corresponding to sub-G1 after serum starvation was observed only in control cells, but not in RUNX3 overexpressing cells (Figure 4C). To demonstrate whether this increment of sub-G1 detected in control cells after serum starvation is due to apoptosis, the level of apoptosis was assessed by using annexin V-FITC/propidium iodide assays (Figure 4D). Annexin V/propidium iodide double-positive cells were observed in 1.8% of RUNX3 overexpressing cells, while in 21.7% of control cells, indicating that RUNX3 overexpression inhibited serum starvation induced apoptosis. To confirm these phenotypes, we examined the knockdown of RUNX3 in Ca9-22 cells, which showed RUNX3 overexpression and were resistant to serum starvation-induced apoptosis. For knockdown of RUNX3, we used three different siRNAs (si-RUNX3-1, si-RUNX3-2 and si-RUNX3-3) and their cocktail. RUNX3 expression was remarkably silenced by si-RUNX3-1 (Figure S3A). Therefore, we used si-RUNX3-1 for the following studies. RUNX3 siRNA transfection reduced the expression of RUNX3 mRNA and protein in Ca9-22 cells (Figure 5A). We examined if siRNA induced a non-specific interferon stress response. RUNX3 siRNA treatment did not induce classic interferon-responsive genes, OAS1 and ISG54 mRNAs, indicating that RUNX3 siRNA treatment did not induce significant interferon response (Figure S3B). As we expected, RUNX3 siRNA inhibited the cell growth (Figure 5B). At 6day, number of RUNX3 siRNA treated cells was remarkably lower than that of control cells. Moreover, RUNX3 siRNA increased the population corresponding to sub-G1 after serum starvation (Figure 5C). Annexin V/propidium iodide double-positive cells were observed in 10.5% of control cells, while in 18.1% of RUNX3 knockdown cells (Figure 5D).
###end p 52
###begin title 53
RUNX3 overexpression promoted cell growth and inhibited serum starvation induced apoptosis.
###end title 53
###begin p 54
A: Generation of RUNX3 overexpressing cells. The RUNX3/pcDNA3 plasmid or the vector alone was introduced into HSC3 cells, and the stable pool clones were obtained by G418 selection for 2 weeks. Exogenous expression of RUNX3 mRNA and protein was examined by RT-PCR and Western blot analysis (WB). Cul1 was used as a loading control. B: The graph shows cell growth of RUNX3 overexpressing and control HSC3 cells. Cells were plated on 24 well plates, and trypsinized cells were counted by Cell Counter (Coulter Z1) at 0, 2, 4 and 6 day. C: RUNX3 overexpression inhibited the serum starvation induced apoptosis. Cells were incubated for 0, 48 and 96 hours after serum starvation and fixed in 70% ethanol. Cell cycle distribution was determined by DNA content analysis after propidium iodide staining using a flow cytometer. For each sample, 20,000 events were stored. We performed two independent experiments. D: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 overexpressing cells after serum starvation for 96 h. We performed two independent experiments.
###end p 54
###begin title 55
RUNX3 knockdown inhibited cell growth and enhanced serum starvation induced apoptosis.
###end title 55
###begin p 56
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
A: RUNX3 silencing by small interfering RNA. Logarithmically growing Ca9-22 cells with RUNX3 expression were seeded at a density of 105cells/6 cm dish and transfected with oligos twice (at 24 and 48 hr after replating). Forty-eight hours after the last transfection, cells were collected and RUNX3 mRNA and protein expression was examined by RT-PCR and Western blot analysis. B: The graph shows that cell growth of RUNX3 siRNA treated and control Ca9-22 cells. Cells were plated on 24 well plates, and trypsinized cells were counted by Cell Counter at 0, 2, 4 and 6 day. C: RUNX3 siRNA enhanced the serum starvation induced apoptosis. Cell cycle distribution was determined by DNA content analysis after propidium iodide staining using a flow cytometer. For each sample, 20,000 events were stored. We performed two independent experiments. D: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 knockdown cells after serum starvation for 96 h. We performed two independent experiments.
###end p 56
###begin p 57
###xml 139 147 139 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g006">Figure 6</xref>
###xml 485 494 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g006">Figure 6A</xref>
###xml 683 692 671 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g006">Figure 6B</xref>
###xml 793 802 781 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g006">Figure 6C</xref>
In addition, we examined the inhibition of apoptosis after treatment with chemotherapeutic drug in control and RUNX3 overexpressing HNSCC (Figure 6). Control and RUNX3 overexpressing HSC3 cells were exposed for 72 hours to adriamycin (DOX; 0.5 and 1 microg/ml), which is a chemotherapeutic agent commonly used in the treatment of HNSCC. The sub-G1 population of RUNX3 overexpressing HSC3 cells was 7.49%, while that of control cells was 44.76% after treatment with 1 microg/ml of DOX (Figure 6A). Moreover, after treatment with 1 microg/ml of DOX, Annexin V/propidium iodide double-positive cells were observed in 25.2% of control cells, while in 8.9% of RUNX3 overexpressing cells (Figure 6B). On the other hand, Annexin V/propidium iodide double-positive cells increased by RUNX3 knockdown (Figure 6C). Overall these suggest that RUNX3 overexpression may be involved in HNSCC development through promoting cell growth and inhibition of apoptosis.
###end p 57
###begin title 58
RUNX3 overexpression inhibited chemotherpeutic drug induced apoptosis.
###end title 58
###begin p 59
A: Adriamycin (Dox, 0, 0.5 and 1 microg/ml) was treated for 72 hours in control and RUNX3 overexpressing HSC3 cells. Cell cycle distribution was determined by DNA content analysis after propidium iodide staining using a flow cytometer. For each sample, 20,000 events were stored. Percentage of sub-G1 population is indicated. We performed two independent experiments with triplicate wells per condition. Representative data is shown. B: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 overexpressing cells after DOX treatment for 72 h at the indicated doses. C: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 knockdown cells after DOX treatment for 72 h at the indicated doses. We performed two independent experiments.
###end p 59
###begin p 60
###xml 173 191 173 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s006">Figure S4A and S4B</xref>
###xml 302 312 302 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s006">Figure S4B</xref>
###xml 374 392 374 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s006">Figure S4C and S4D</xref>
###xml 498 508 498 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s006">Figure S4D</xref>
To know the role of RUNX3 in tumorigenesis, we examined the tumorsphere formation by using ultra low attachment plates. RUNX3 overexpression promoted tumorsphere formation (Figure S4A and S4B). The average number of colonies was 535.6 and 663.3 in control and RUNX3 overexpressing cells, respectively (Figure S4B). Moreover, RUNX3 knockdown inhibited tumorsphere formation (Figure S4C and S4D). The average number of colonies was 566.0 and 161.3 in control and RUNX3 knockdown cells, respectively (Figure S4D).
###end p 60
###begin p 61
###xml 274 284 274 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s009">Dataset S1</xref>
###xml 287 295 287 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s002">Table S2</xref>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Draghici1">[22]</xref>
###xml 624 634 624 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s007">Figure S5A</xref>
###xml 930 948 930 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s007">Figure S5A and S5B</xref>
###xml 1100 1118 1100 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s007">Figure S5A and S5B</xref>
###xml 1377 1380 1376 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Bae1">[2]</xref>
###xml 1382 1385 1381 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 1473 1477 1471 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-FrancisWest1">[23]</xref>
###xml 1564 1568 1562 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Lau1">[20]</xref>
###xml 1841 1851 1838 1848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s008">Figure S6A</xref>
###xml 2017 2027 2014 2024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s008">Figure S6B</xref>
###xml 2346 2356 2343 2353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s008">Figure S6C</xref>
###xml 1550 1555 <span type="species:ncbi:10090">mouse</span>
Moreover, we compared the gene transcriptional profiles between control and RUNX3 overexpressing HSC3 cells. By microarray analysis, 1251 genes were selectively up-regulated (over 2-fold) and 472 genes were down-regulated (less than 0.5) in RUNX3 overexpressing HSC3 cells (Dataset S1). Table S2 shows the list of up-regulated genes (over 15-fold) and down-regulated genes (less than 0.1) in RUNX3 overexpressing HSC3 cells, respectively. Then, we used the computer program Onto-Express to analyze the identified oxidized mRNA species and grouped them according to cellular component or molecular function [22]. As shown in Figure S5A, 1251 genes that were up-regulated by RUNX3 overexpression in HNSCC cells were classified into gene ontology categories according to involvement in different biological processes. Interestingly, up-regulated genes by RUNX3 overexpression belong to apoptosis, cell cycle and signal transduction (Figure S5A and S5B). Moreover, some genes were classified as being involved in keratinocyte differentiation, keratinocyte proliferation and response to serum starvation (Figure S5A and S5B). Thus, these focused genes potentially are important for apoptosis, cell growth and cellular differentiation by RUNX3 overexpression. RUNX3 is known as a nuclear effecter of the TGF-ss/BMP pathways, and a key tumor suppressor gene in the gastric epithelium [2], [3]. In vertebrate facial development, BMPs, TGF-ss, Shh and FGFs are known to be involved [23]. In addition, Runx3 is expressed in the tongue and palate epithelium of mouse embryos [20]. Therefore, we suggest that RUNX3 may be involved in the development of oral mucosa through growth factor signaling pathways. HNSCC cell line, HOC621 cells with lower expression of RUNX3 mRNA were treated with growth factors including TGF-ss1, IGF, EGF, bFGF and PDGF-AA (Figure S6A). Among these growth factors, EGF significantly enhanced RUNX3 expression in HOC621 cells. EGF enhanced RUNX3 expression in concentration and time dependent manner (Figure S6B). However, RUNX3 expression was not induced by growth factor stimulation in other HNSCC cells without RUNX3 expression due to methylation (data not shown). Moreover, we examined the expression of EGF and EGFR and compared with RUNX3 expression. Interestingly, EGF expression was well correlated with RUNX3 expression (Figure S6C).
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 138 141 138 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 142 145 142 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim1">[5]</xref>
###xml 292 295 292 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim1">[5]</xref>
###xml 296 299 296 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Yanada1">[8]</xref>
###xml 446 449 446 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 616 625 616 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g001">Figure 1C</xref>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Cheng1">[17]</xref>
###xml 727 731 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Lau1">[20]</xref>
###xml 854 863 854 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s003">Figure S1</xref>
###xml 1040 1044 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-SaltoTellez1">[13]</xref>
###xml 1330 1338 1330 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g002">Figure 2</xref>
###xml 1340 1344 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-SaltoTellez1">[13]</xref>
###xml 1492 1495 1492 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Ito2">[4]</xref>
###xml 1497 1500 1497 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim1">[5]</xref>
###xml 1746 1750 1746 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Cameronm1">[24]</xref>
###xml 1752 1756 1752 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Yanagida1">[25]</xref>
###xml 1820 1829 1820 1829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g004">Figure 4B</xref>
###xml 1834 1836 1834 1836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g005">5B</xref>
###xml 2157 2165 2157 2165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2182 2191 2182 2191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g004">Figures 4</xref>
###xml 2192 2192 2192 2192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g005"/>
###xml 2192 2193 2192 2193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g006">6</xref>
###xml 2301 2310 2301 2310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s006">Figure S4</xref>
###xml 2431 2438 2431 2438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005892-t001">Table 1</xref>
###xml 2610 2618 2610 2618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s002">Table S2</xref>
###xml 2864 2868 2864 2868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Wente1">[26]</xref>
###xml 3061 3065 3061 3065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Hoeflich1">[27]</xref>
###xml 3115 3119 3115 3119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Iiizumi1">[28]</xref>
###xml 3344 3353 3344 3353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005892.s007">Figure S5</xref>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 1733 1738 <span type="species:ncbi:10090">mouse</span>
RUNX3 is inactivated in more than 80% of human gastric cancer by CpG island hypermethylation, protein mislocalization and point mutations [3]-[5]. Moreover, it has been reported that reduced expression of RUNX3 was observed in various cancers including bladder, liver, colon and lung cancers [5]-[8]. In fact, gastric mucosa of Runx3-null mice develops hyperplasia due to the stimulated proliferation and suppressed apoptosis of epithelial cells [3]. Taken together, RUNX3 acts as a tumor suppressor in various cancers. In this study, we confirmed the low expression of RUNX3 in various cancer cell lines by RT-PCR (Figure 1C). Expression level of RUNX3 was well correlated with methylation status, as previously reported [17]-[20]. By immunohistochemistry, RUNX3 expression was observed in normal colon mucosa, while cancer cells did not express RUNX3 (Figure S1). Contrary to these tumors, here we found oncogenic roles for RUNX3 in HNSCC. It recently has been shown that RUNX3 overexpression was observed in basal cell carcinoma of skin [13]. This distinct role in HNSCC and skin basal cell carcinoma may be accounted for by the pathogenesis of both types of cancer, which arise from squamous epithelium. In fact, RUNX3 frequency of RUNX3 positive cells is low in adult skin and oral mucosa, while most cancer cells expressed (Figure 2) [13]. Overexpression of RUNX3 has previously been associated with functional mutations or protein mislocalization in breast, gastric and bladder tumors [4], [5]. However, functional mutations or protein mislocalization were not found in HNSCC, indicating that RUNX3 is fully functional in HNSCC cells. All members of the RUNX family, most notably Runx2, are known to promote tumorigenecity in mouse models [24], [25]. In fact, RUNX3 overexpression promoted cell proliferation. In Figure 4B and 5B, RUNX3 overexpression or knockdown affected to the cell growth from 4 day after plating. Therefore, RUNX3 may be involved in allowance for high cell density in addition to stimulation of cell growth. Moreover, RUNX3 overexpression inhibited serum starvation induced apoptosis and chemotherapeutic drug induced apoptosis in vitro in HNSCC cells (Figures 4-6). Interestingly, RUNX3 overexpression promoted tumorigenesis, demonstrated by tumorsphere formation assay (Figure S4). These findings may be implicated in RUNX3 related malignant behaviors of HNSCC including invasiveness and metastasis (Table 1). Comparing the gene expression profile between control and RUNX3 overexpressing HNSCC cells revealed that several genes were selectively up-regulated and down-regulated (Table S2). CXCL14, IGFBP2 and EphA4 receptor were up-regulated, and fibronectin 1 was down-regulated in RUNX3 overexpressing HNSCC cells. Although CXCL14 suppresses tumor growth in some type of cancer, CXCL14 is involved in invasion of pancreatic cancer [26]. Moreover, IGFBP-2 is a highly sensitive marker of malignant progression in different tumors and potentially involved in anti-apoptosis, angiogenesis, and metastasis during cancer progression [27]. EphA4 receptor also promotes cancer cell growth [28]. In addition, classification into gene ontology categories according to involvement in different biological processes showed that several genes involved in apoptosis and cell cycle were up-regulated by RUNX3 overexpression (Figure S5). It is interesting to examine the correlation between RUNX3 and these molecules. The findings identified by microarray analysis may help future experiments for clarifying the detailed role of RUNX3 in the development of HNSCC.
###end p 63
###begin p 64
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Razin1">[29]</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Razin2">[30]</xref>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Lau1">[20]</xref>
###xml 601 610 601 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3E</xref>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 731 747 731 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3H and 3I</xref>
###xml 1120 1136 1120 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g003">Figure 3C and 3D</xref>
###xml 1263 1271 1263 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g007">Figure 7</xref>
###xml 1396 1400 1396 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-GamaSosa1">[31]</xref>
###xml 1402 1406 1402 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Kim3">[32]</xref>
###xml 1539 1543 1539 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Borrello1">[33]</xref>
###xml 1544 1548 1544 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Lipsanen1">[36]</xref>
###xml 406 411 <span type="species:ncbi:10090">mouse</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
###xml 1526 1531 <span type="species:ncbi:9606">human</span>
DNA methylation plays an important role in the establishment and maintenance of the program of gene expression. The pattern of 5-methylcytosine distribution in the genome is unique for each cell type and is established in embryogenesis as a result of balance between DNA methylation and demethylation [29], [30]. It recently has been revealed that Runx3 is expressed in the tongue and palate epithelium of mouse embryos and Runx3 expression disappears in newborn mice [20]. Here, we also confirmed that Runx3 expression was observed in tongue epithelium of embryo, but not in adult tongue epithelium (Figure 3E). Interestingly, we demonstrated that RUNX3 methylation of its promoter region was observed in normal epithelial cells (Figure 3H and 3I), suggesting that RUNX3 may be silenced by methylation in adult normal oral epithelium. However, there may be another possibility, such as transcriptional modulation by traditional activators or repressors, in addition to the regulation of RUNX3 expression by methylation. Moreover, methylation of its promoter region was observed in HNSCC cells without RUNX3 expression (Figure 3C and 3D). Therefore, these findings indicate that RUNX3 expression in HNSCC may be caused by demethylation during cancer development (Figure 7). In malignant tumor, the level of general demethylation and the frequency of demethylation increase with tumor progression [31], [32], and demethylation of individual CpG dinucleotides located in C-MYC, Ha RAS, and ERB-A1 proto-oncogene was revealed in human tumors [33]-[36]. Detailed mechanism of RUNX3 regulation in normal adult oral epithelium and HNSCC requires further experiments.
###end p 64
###begin title 65
Schematic model of RUNX3 overexpression in HNSCC.
###end title 65
###begin p 66
In oral epithelium of embryo, RUNX3 is expressed and may be induced by some signaling pathways such as BMP/TGF-ss, Shh and FGF. After birth, RUNX3 may be methylated of its promoter and/or transcriptional repression in oral epithelial cells. RUNX3 may be caused by demethylation or transcriptional modulation during cancer development. In aggressive HNSCC, unknown stimulation may enhance RUNX3 expression.
###end p 66
###begin p 67
###xml 68 71 68 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Nam1">[37]</xref>
###xml 331 334 330 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Bae1">[2]</xref>
###xml 336 339 335 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-Li1">[3]</xref>
###xml 427 431 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005892-FrancisWest1">[23]</xref>
###xml 878 886 874 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005892-g007">Figure 7</xref>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 114 124 <span type="species:ncbi:6239">C. elegans</span>
RUNX3 is expressed in the gastrointestinal tract of mouse and human [3], and RNT, a homolog of the RUNX family in C. elegans, is involved in the development of a functional epidermis and gut [37]. RUNX3 is known as a nuclear effector of the functional BMP/TGF-ss pathways, and a key tumor suppressor gene in the gastric epithelium [2], [3]. In vertebrate facial development, BMPs, TGF-ss, Shh and FGFs are known to be involved [23]. As RUNX3 expression in tongue and palatal epithelium is observed only in embryonic stage, RUNX3 may be involved in the development of oral mucosa through some signaling pathways such as TGF-ss/BMP, Shh and FGF. We treated growth factors such as TGF-ss1, IGF, EGF, bFGF, and PDGF-AA in HNSCC cells with RUNX3 expression and found that EGF enhanced RUNX3 expression. In HNSCC, RUNX3 overexpression may be caused by some stimulation including EGF (Figure 7). To know the mechanism of RUNX3 overexpression in HNSCC requires further studies.
###end p 67
###begin p 68
Overall we suggest that i) RUNX3 has an oncogenic role in HNSCC, ii) RUNX3 expression observed in HNSCC may be caused in part by demethylation during cancer development, and iii) RUNX3 expression can be a useful marker for predicting malignant behavior and the effect of chemotherapeutic drugs in HNSCC.
###end p 68
###begin title 69
Supporting Information
###end title 69
###begin p 70
(0.05 MB PPT)
###end p 70
###begin p 71
Click here for additional data file.
###end p 71
###begin p 72
(0.12 MB DOC)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
(0.35 MB TIF)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
(0.39 MB TIF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
(0.17 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
(0.31 MB TIF)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
(0.90 MB TIF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
(0.20 MB TIF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
(0.88 MB XLS)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
We thank Dr. Gaffney (University of Minnesota Medical School) for providing us the Gene Chips data of 41 primary HNSCC and 13 normal tissues, Dr. Kamata (Hiroshima University) for providing us the HNSCC cell lines, Dr. Shimamoto (Prefectural University of Hiroshima) for providing us the specimens of colon cancer, Dr. Tahara (Hiroshima University) for providing us the cancer cell lines, Ms. Imaoka (Nihon University School of Dentistry at Matsudo) for supporting microarray analysis and Dr. Siriwardena (Hiroshima University) for technical assistance. We also thank Dr. Ito Y and Dr. Ito K (Institute of Molecular and Cell Biology, Singapore) for providing reagents and helpful discussion.
###end p 88
###begin title 89
References
###end title 89
###begin article-title 90
Oncogenic potential of the RUNX gene family: 'Overview'.
###end article-title 90
###begin article-title 91
Cloning, mapping and expression of PEBP2aC, a third gene encoding the mammalian runt domain.
###end article-title 91
###begin article-title 92
Causal relationship between the loss of RUNX3 expression and gastric cancer.
###end article-title 92
###begin article-title 93
RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization.
###end article-title 93
###begin article-title 94
RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
###end article-title 94
###begin article-title 95
Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
###end article-title 95
###begin article-title 96
###xml 84 89 <span type="species:ncbi:9606">human</span>
Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma.
###end article-title 96
###begin article-title 97
###xml 91 96 <span type="species:ncbi:9606">human</span>
Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines.
###end article-title 97
###begin article-title 98
###xml 41 46 <span type="species:ncbi:9606">human</span>
Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma.
###end article-title 98
###begin article-title 99
Focus on head and neck cancer.
###end article-title 99
###begin article-title 100
###xml 35 40 <span type="species:ncbi:9606">human</span>
Critical factors in the biology of human cancer metastasis: Twenty-eighth GHA Clowes Memorial Award Lecture.
###end article-title 100
###begin article-title 101
Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck.
###end article-title 101
###begin article-title 102
###xml 34 39 <span type="species:ncbi:9606">human</span>
RUNX3 protein is overexpressed in human basal cell carcinomas.
###end article-title 102
###begin article-title 103
Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation.
###end article-title 103
###begin article-title 104
Spreading of methylation within Runx3 CpG island in gastric cancer.
###end article-title 104
###begin article-title 105
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.
###end article-title 105
###begin article-title 106
Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia.
###end article-title 106
###begin article-title 107
Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers.
###end article-title 107
###begin article-title 108
Frequent Loss of RUNX3 Expression by Promoter Hypermethylation in Gastric Carcinoma.
###end article-title 108
###begin article-title 109
RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer.
###end article-title 109
###begin article-title 110
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
Runx3 expression during mouse tongue and palate development.
###end article-title 110
###begin article-title 111
Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate.
###end article-title 111
###begin article-title 112
Signaling interactions during facial development.
###end article-title 112
###begin article-title 113
The Runx genes: lineage-specific oncogenes and tumor suppressors.
###end article-title 113
###begin article-title 114
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
###end article-title 114
###begin article-title 115
CXCL14 expression and potential function in pancreatic cancer.
###end article-title 115
###begin article-title 116
Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?
###end article-title 116
###begin article-title 117
EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.
###end article-title 117
###begin article-title 118
DNA methylation and gene function.
###end article-title 118
###begin article-title 119
DNA methylation in early development.
###end article-title 119
###begin article-title 120
###xml 41 46 <span type="species:ncbi:9606">human</span>
The 5-methylcytosine content of DNA from human tumors.
###end article-title 120
###begin article-title 121
Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma.
###end article-title 121
###begin article-title 122
###xml 56 61 <span type="species:ncbi:9606">human</span>
DNA methylation of coding and non-coding regions of the human H-RAS gene in normal and tumor tissues.
###end article-title 122
###begin article-title 123
###xml 26 31 <span type="species:ncbi:9606">human</span>
Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene.
###end article-title 123
###begin article-title 124
###xml 44 49 <span type="species:ncbi:9606">human</span>
Hypomethylation of ras oncogenes in primary human cancers.
###end article-title 124
###begin article-title 125
###xml 71 76 <span type="species:ncbi:9606">human</span>
Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia.
###end article-title 125
###begin article-title 126
###xml 97 119 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
Expression pattern, regulation, and biological role of Runt domain transcription factor, run, in Caenorhabditis elegans.
###end article-title 126
###begin article-title 127
Histologic classification and grading of malignancy in carcinoma of the larynx.
###end article-title 127
###begin p 128
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 128
###begin p 129
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The research was supported by grants-in-aid from the Ministry of Education, Science and Culture of Japan (YK and TT) and Satake education and research grant (YK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 129

